Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > Calevia Inc. to Develop Graphene-based, Non-Invasive Cancer Eradication Therapies in Partnership with Grafoid Inc. and ProScan Rx Pharma Inc.

Abstract:
ProScanRxPharma Inc. and Grafoid Inc announced today the formation of Calevia Inc., an entirely new cancer therapeutic nanotechnology platform for the precise targeting and thermal eradication of solid tumors.

Calevia Inc. to Develop Graphene-based, Non-Invasive Cancer Eradication Therapies in Partnership with Grafoid Inc. and ProScan Rx Pharma Inc.

Montreal, Canada | Posted on September 7th, 2013

Calevia intends to combine ProScan's cellular antibody targeting technologies with MesoGraf™Xide graphene supplied by Grafoid Inc. to eradicate cancerous cells in a non-invasive manner.

Mesograf™ Xide is a unique, functionalized, photoresponsive graphene material that may be coupled with ProScan' s selective molecular targeting antibody ligands to create a photothermal bio-conjugate for the treatment of prostate cancer. Grafoid's Mesograf™ derivative Mesograf™Xide is the latest development in thermal energy generating nanomaterial science that instantly transforms near infrared (NIR) light into heat.

As a result of targeting, the heat generating bio-conjugate is delivered selectively to tumor cells and remotely activated by harmless NIR light to safely and effectively destroy cancer tissue from within in a physically powerful way, heat. Calevia's targeted photothermal therapy may overcome the side effects and strong limitations of common therapeutic methods such as surgery, radiation and chemotherapy.

Focal therapy is the focus of significant development by the pharmaceutical industry. Calevia believes that photothermal therapy using heat as the treatment modality represents a very innovative approach to focal cancer treatment. Calevia will first target prostate cancer using Proscan's anti-PSMA antibody. The platform will be developed subsequently for several solid tumor types.

Dr Vezeau, co-founder of Calevia said the combination of cell targeting at the molecular level with Grafoid's MesoGraf™Xide could ultimately redefine the way medicine treats several forms of solid tumors. "That is our goal."

He added that Calevia's targeted photothermal treatment opens the door to an entirely new therapeutic platform that overcomes the deficiencies inherent in traditional therapies.

"Targeting the photothermal ablation of prostate and subsequently other solid cancers bridges the gap between conventional therapies and today's nanotechnology revolution," Dr. Vezeau said.

Calevia's co-founders Dr. Claude Vezeau serves as President and CEO, and Dr. Serge Moffett serves as Vice-President, Research and Development. Dr. Gordon Chiu, B.Sci., M.Sci., f-M.S.T.P., N.D. and Vice-President of Grafoid Inc., serves as co-manager and advisor to the project.

Grafoid Inc. has invested in Calevia Inc. and will co-manage the early stage venture. Grafoid is also involved with the arrangement of Calevia's next stage and longer-term financing.

Dr. Vezeau will be presenting Calevia at the Rodman & Renshaw Global Investment Conference in New York, September 8-10, 2013.

About ProScanRxPharma Inc.

ProScanRxPharma Inc. is an experienced developer of targeted monoclonal antibodies. ProScan is dedicated to the development of innovative solutions to improve and simplify the clinical management of patients suffering from prostate cancer. It applies modern technologies to develop new molecular tools to provide clinicians and their cancer patients with efficient diagnostic and treatment alternatives. ProScan's products are expected to bring a new wave of solutions to clinicians and patients for the safer and more efficient detection and control of prostate cancer.

About Grafoid Inc.

Grafoid Inc. is a privately held Canadian corporation investing in graphene applications and economically scalable production processes for MesoGraf™ - the global standard for graphene - and MesoGraf™Xide its trade mark graphene oxide produced from raw, unprocessed graphite ore. Focus Graphite Inc. (TSX VENTURE:FMS)(OTCQX:FCSMF)(FRANKFURT:FKC) holds a principal interest in Grafoid on behalf of its shareholders.

Forward Looking Statements - Disclaimer

This news release may contain forward looking statements, being statements which are not historical facts, and discussions of future plans and objectives. There can be no assurance that such statements will prove accurate. Such statements are necessarily based upon a number of estimates and assumptions that are subject to numerous risks and uncertainties that could cause actual results and future events to differ materially from those anticipated or projected.

####

For more information, please click here

Contacts:
ProScanRxPharma Inc.
Dr. Claude Vezeau
514-908-0660

www.proscanrxpharma.com
www.calevia.com

Grafoid Inc.
Dr. Gordon Chiu
Vice-President
613-691-1091 ext 104

www.grafoid.com

Copyright © Marketwire

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Malvern’s Dr Alan Rawle talks TLAs in plenary lecture at Particulate Systems Analysis conference August 21st, 2014

Water window imaging opportunity: A new theoretical study elucidates mechanisms that could help in producing coherent radiations, ultimately promoting high-contrast imaging of biological samples August 21st, 2014

Nanotechnology Helps Production of Super Adsorbent Polymers August 21st, 2014

Graphene may be key to leap in supercapacitor performance August 20th, 2014

Newly-Developed Nanobiosensor Quickly Diagnoses Cancer August 20th, 2014

Graphene

Graphene may be key to leap in supercapacitor performance August 20th, 2014

Ultrasonic Waves Applied in Production of Graphene Nanosheets August 20th, 2014

Nanomedicine

Nanotechnology Helps Production of Super Adsorbent Polymers August 21st, 2014

Newly-Developed Nanobiosensor Quickly Diagnoses Cancer August 20th, 2014

Graphene rubber bands could stretch limits of current healthcare, new research finds August 19th, 2014

Interaction between Drug, DNA for Designing Anticancer Drugs Studied in Iran August 17th, 2014

Announcements

Malvern’s Dr Alan Rawle talks TLAs in plenary lecture at Particulate Systems Analysis conference August 21st, 2014

Water window imaging opportunity: A new theoretical study elucidates mechanisms that could help in producing coherent radiations, ultimately promoting high-contrast imaging of biological samples August 21st, 2014

Nanotechnology Helps Production of Super Adsorbent Polymers August 21st, 2014

Ultrasonic Waves Applied in Production of Graphene Nanosheets August 20th, 2014

Events/Classes

Malvern’s Dr Alan Rawle talks TLAs in plenary lecture at Particulate Systems Analysis conference August 21st, 2014

The International Space Elevator Consortium (ISEC) is proud to announce the 2014 Space Elevator Conference! This annual event will be held at the Museum of Flight in Seattle, Washington from Friday, August 22nd through Sunday, August 24th August 19th, 2014

KaSAM-2014 International Conference (September 7-10, 2014, Kathmandu, Nepal) August 19th, 2014

Harris & Harris Group to Host Conference Call on Second-Quarter 2014 Financial Results on August 15, 2014 August 12th, 2014

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE